
Intellaif
Our AI-driven solution evaluates preclinical models in silico, improving translational accuracy and de-risking early-stage drug development.
Majority of drug candidates fail at clinical trials. This means that much resources are wasted and patients do not receive the treatment they need in a timely manner. This potentially leads to expensive medicine, loss of wellbeing, and inefficiency in drug development. We are developing an AI-driven solution that makes drug development safer and more efficacious. This is done by validation of the preclinical models used in the investigation of lead drug candidates. Preclinical models refer to animal based, and laboratory based methods that investigate drug candidates for efficacy and safety. Our solution is data driven, AI driven and highly scalable. Overall this solution aims to de-risk the drug development process, saves lives and billions of euros in resources.